Introduction
Von Willebrand disease (VWD) is an inherited bleeding disorder characterized by qualitative and/or quantitative defects of von Willebrand factor (VWF), a circulating glycoprotein required for hemostasis. Von Willebrand disease has an estimated prevalence of approximately 0.01% and manifests clinically with hemorrhage after invasive procedures [1] . Although bleeding risks in VWD are established, perioperative thrombotic complications in patients with VWD are not well characterized [2, 3] . Prior studies in nonsurgical cohorts have reported lower rates of cardiovascular disease in patients with VWD [4, 5] . We investigated the association between a diagnosis of VWD and bleeding and thrombotic outcomes following major non-cardiac surgery in a large national database from the United States.
Methods
Patients age ≥45 years requiring major non-cardiac surgery were identified from Healthcare Cost and Utilization Project's National Inpatient Sample data from 2004 to 2013, as previously described [6] . Patients were included if they had a principal International Classification of Diseases, Ninth Revision (ICD-9) procedure code for a major therapeutic operating room procedure (HCUP Procedure Class 4). Principal CCS procedure codes, which represent aggregates of relevant primary ICD-9 procedure codes by surgical subtype, were used to exclude patients who underwent cardiac procedures (n = 1,655,567), cardiac surgery and cardiac Abstract Von Willebrand disease (VWD) is an inherited bleeding disorder that often manifests clinically with hemorrhage after invasive procedures. We investigated the association between a diagnosis of VWD and bleeding and thrombotic outcomes following major non-cardiac surgery in a large national database from the United States. Patients age ≥45 years requiring major non-cardiac surgery were identified from Healthcare Cost and Utilization Project's National Inpatient Sample data. Von Willebrand disease, perioperative major adverse cardiovascular events (MACE), thrombotic events, and hemorrhage were defined by ICD9 diagnosis codes. From 2004 to 2013, a total of 10,581,621 hospitalizations for major non-cardiac surgery met study inclusion criteria and VWD was identified in 3765 (0.036%). In adjusted analyses, patients with VWD were significantly more likely to develop postoperative hemorrhage than patients without VWD (5.5 vs. 1.9%, p < 0.001; adjusted OR 3.49, 95% CI 3.03-4.03), but had similar odds of perioperative MACE and thrombotic events. Thus, a diagnosis of VWD was associated with increased risks of bleeding with non-cardiac surgery, without a corresponding reduction in perioperative thrombosis in comparison to patients without VWD. Perioperative management of patients with hereditary bleeding disorders and mitigation of thrombotic risks requires further study. transplantation (n = 582,726), bone marrow transplantation (n = 18,151), ophthalmologic surgery (n = 13,342), radiation therapy (n = 9817), dental surgery (n = 1779), and non-operating room procedures (n = 386) as a principal in-hospital procedure. Von Willebrand disease was identified using ICD-9 diagnosis code 286.4. Perioperative major adverse cardiovascular events (MACE), thrombotic events, and perioperative hemorrhage during the index surgical hospital admission were defined by ICD-9 diagnosis codes ( Table 2 footnote). Multivariable logistic regression models were generated to estimate odds of perioperative events, adjusted for patient demographics, cardiovascular risk factors, and surgery type. Statistical analyses were performed using SPSS 20 (IBM SPSS Statistics, Armonk, NY) and p-values <0.05 were considered to be statistically significant.
Results
From 2004 to 2013, a total of 10,581,621 hospitalizations for major non-cardiac surgery met study inclusion criteria and VWD was identified in 3765 (0.036% Table 2 . However, differences in the frequency of thrombotic outcomes were fully attenuated after adjustment for age, sex, and other clinical variables. In adjusted analyses, patients with VWD were significantly more likely to develop post-operative hemorrhage than patients without VWD (5.5 vs. 1.9%, p < 0.001; adjusted OR 3.49, 95% CI 3.03-4.03). Similar findings were observed in sensitivity analyses of patients with elective surgical hospital admission (data not shown). 
Discussion
Bleeding associated with non-cardiac surgery in patients with VWD remains a major concern. Perioperative management to mitigate the risk of bleeding requires consideration of patients' VWD subtype (qualitative vs. quantitative; partial vs. total VWF deficiency) as well as the specific risks associated with the intended surgical approach. Although preoperative desmopressin is often sufficient prior to minor procedures, the mainstay of therapy is the prophylactic administration of plasma-derived concentrates of VWF, with or without factor VIII, prior to major surgery. Adjunctive therapies, such as intravenous immunoglobulins and tranexamic acid, have also been reported [7, 8] . Although current measures to mitigate surgical bleeding in WVD appear to be safe and well tolerated in small series, effects of pharmacology on perioperative thrombotic risks remain uncertain [7] [8] [9] . In this analysis of patients undergoing non-cardiac surgery, patients with VWD were more likely to have perioperative bleeding than patients without VWD, but had similar risks of perioperative thrombotic events after adjustment for covariates. These results are surprising in light of prior data with lower cardiovascular disease rates in VWD [4, 5] . However, this finding may reflect the unintended, prothrombotic effects of perioperative management of VWD, with administration of red blood cells or VWF-containing concentrates to prevent bleeding or mitigate hemorrhage. Thus, the present analysis demonstrates the complexity of relationships between perioperative bleeding and thrombosis, and highlights the need for further investigation to determine the optimal management of surgical patients with VWD.
There are some notable limitations of this study. Analyses were based on administrative coding data, which may be subject to reporting bias or coding errors. Type and severity of VWD could not be determined. Medical therapy, including administration of VWF-containing concentrates, was not available from this dataset. The analysis was limited to adults ≥45, the population at greatest risk for cardiovascular complications of surgery. Finally, the timing of cardiovascular complications following non-cardiac surgery cannot be firmly established from this administrative dataset.
In conclusion, a diagnosis of VWD was associated with increased risks of bleeding with non-cardiac surgery, without a corresponding reduction in perioperative thrombosis in comparison to patients without VWD. Perioperative management of patients with hereditary bleeding disorders and mitigation of thrombotic risks requires further study. 
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